Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model.

In earlier work, we showed that adeno-associated virus-mediated delivery of a Factor IX gene to skeletal muscle by direct intramuscular injection resulted in therapeutic levels of circulating Factor IX in mice. However, achievement of target doses in humans proved impractical because of the large number of injections required. We used a novel intravascular delivery technique to achieve successful transduction of extensive areas of skeletal muscle in a large animal with hemophilia. We provide here the first report of long-term (> 3 years, with observation ongoing), robust Factor IX expression (circulating levels of 4%-14%) by muscle-directed gene transfer in a large animal, resulting in essentially complete correction of the bleeding disorder in hemophilic dogs. The results of this translational study establish an experimental basis for clinical studies of this delivery method in humans with hemophilia B. These findings also have immediate relevance for gene transfer in patients with muscular dystrophy.

[1]  Yi Zhang,et al.  Erythropoietin gene therapy leads to autoimmune anemia in macaques. , 2004, Blood.

[2]  J. Rasko,et al.  1002. Immune Responses to AAV and to Factor IX in a Phase I Study of AAV-Mediated, Liver-Directed Gene Transfer for Hemophilia B , 2004 .

[3]  N. Casadevall,et al.  1050. Autoimmune Anemia in Macaques Following Erythropoietin Gene Therapy , 2004 .

[4]  R. Schaub,et al.  Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. , 2003, Blood.

[5]  M. Kay,et al.  Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[7]  A. Hafezi-Moghadam,et al.  Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A , 2003, Nature Medicine.

[8]  M. Garcia-Blanco,et al.  Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing , 2003, Nature Medicine.

[9]  A. Eggermont,et al.  Current uses of isolated limb perfusion in the clinic and a model system for new strategies. , 2003, The Lancet. Oncology.

[10]  Alan McClelland,et al.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.

[11]  F. Luyten,et al.  Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long‐terminal repeats , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Herzog,et al.  Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. , 2002, Human gene therapy.

[14]  R. Herzog,et al.  Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.

[15]  T. VandenDriessche,et al.  Therapeutic levels of human Factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A , 2002, The journal of gene medicine.

[16]  N. Boyce.  Trial halted after gene shows up in semen , 2001, Nature.

[17]  J. Biegel,et al.  Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  R. Herzog,et al.  Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  R. Samulski,et al.  Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  R. Herzog,et al.  Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  J. Wilson,et al.  Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  R. Ljung,et al.  Haemophilia B mutations in Sweden: a population‐based study of mutational heterogeneity , 2001, British journal of haematology.

[23]  M. Kay,et al.  Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. , 2000, Blood.

[24]  R. Samulski,et al.  The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. , 2000, Human gene therapy.

[25]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[26]  T. VandenDriessche,et al.  Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Kayda,et al.  In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice. , 1999, Human gene therapy.

[28]  J. Wolff,et al.  High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. , 1999, Human gene therapy.

[29]  James M. Wilson,et al.  Gene Therapy Vectors Based on Adeno-Associated Virus Type 1 , 1999, Journal of Virology.

[30]  R. Balice-Gordon,et al.  Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector , 1999, Nature Medicine.

[31]  B. Vrouenraets,et al.  Toxicity and morbidity of isolated limb perfusion. , 1998, Seminars in surgical oncology.

[32]  P. Kam,et al.  Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. , 1998, Seminars in surgical oncology.

[33]  C. Steer,et al.  In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides , 1998, Nature Medicine.

[34]  M. Strauss.  The site-specific correction of genetic defects , 1998, Nature Medicine.

[35]  R. Samulski,et al.  Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions , 1998, Journal of Virology.

[36]  A. Gown,et al.  Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors , 1997, Nature Genetics.

[37]  James M. Wilson,et al.  Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Lee,et al.  INVESTIGATION OF CHRONIC HEPATITIS C INFECTION IN INDIVIDUALS WITH HAEMOPHILIA , 1997, British journal of haematology.

[39]  P. Simmonds,et al.  Investigation of chronic hepatitis C infection in individuals with haemophilia: assessment of invasive and non‐invasive methods , 1996, British journal of haematology.

[40]  D. Bentley,et al.  Haemophilia B mutations in a complete Swedish population sample: a test of new strategy for the genetic counselling of diseases with high mutational heterogeneity , 1991, British journal of haematology.

[41]  G. Brayer,et al.  Canine hemophilia B resulting from a point mutation with unusual consequences. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[42]  L. Bianchi,et al.  A study of liver biopsies and liver disease among hemophiliacs. , 1985, Blood.

[43]  R. Herzog,et al.  Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. , 2004, Blood.

[44]  R. Morgan,et al.  Toxicity of a first-generation adenoviral vector in rhesus macaques. , 2002, Human gene therapy.

[45]  D. Kayda,et al.  Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  R. Herzog,et al.  Posttranslational modifications of recombinant myotube-synthesized human factor IX. , 2001, Blood.

[47]  M. Kaleko,et al.  Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. , 2001, Blood.

[48]  Katherine A. High,et al.  Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector , 1999, Nature Medicine.